GLP1R and type 2 diabetes mellitus: Some glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated CV benefits, [7–10] and generally a neutral to modest reduction in BP, making them a preferred treatment option in patients with T2D with indicators of high-risk of established atherosclerotic CV disease [11].